Drugs of the Future : Impact Factor & More
eISSN: 2013-0368pISSN: 0377-8282
Share this on:
Key Metrics
CiteScore 
0.2
Impact Factor
< 5
SJR
Q4Pharmacology
SNIP
0.06
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Drugs of the Future
Drugs of the Future Journal Specifications
Indexed in the following public directories
Scopus 
SJR
| Overview | |
| Publisher | PROUS SCIENCE, SAU-THOMSON REUTERS |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1976 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Drugs of the Future ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Drugs of the Future
American Society of Hematology - 64th Annual Meeting and Exposition. New Orleans - December 10-13, 2022
- 1 Mar 2023
- Drugs of the Future
Pipeline on the Move
- 1 Mar 2023
- Drugs of the Future
Spesolimab. Anti-IL-36R monoclonal antibody, Treatment of generalized pustular psoriasis, Treatment of immune-mediated inflammatory diseases
- 1 Mar 2023
- Drugs of the Future
Recent trends in medicinal chemistry and enabling technologies. Highlights from the Society for Medicines Research Conference. London - December 8, 2022
- 1 Mar 2023
- Drugs of the Future
Tirzepatide. Dual GLP-1/GIP receptor agonist, Treatment of type 2 diabetes and obesity
- 1 Mar 2023
- Drugs of the Future
Bimiralisib. Phosphatidylinositol 3-kinase (PI3K)/mechanistic target of rapamycin (mTOR) inhibitor, Treatment of solid tumors, Treatment of lymphoma
- 1 Mar 2023
- Drugs of the Future
American Society of Hematology - 64th Annual Meeting and Exposition. New Orleans - December 10-13, 2022
- 1 Mar 2023
- Drugs of the Future
Pipeline on the Move
- 1 Mar 2023
- Drugs of the Future
Spesolimab. Anti-IL-36R monoclonal antibody, Treatment of generalized pustular psoriasis, Treatment of immune-mediated inflammatory diseases
- 1 Mar 2023
- Drugs of the Future
Recent trends in medicinal chemistry and enabling technologies. Highlights from the Society for Medicines Research Conference. London - December 8, 2022
- 1 Mar 2023
- Drugs of the Future
Tirzepatide. Dual GLP-1/GIP receptor agonist, Treatment of type 2 diabetes and obesity
- 1 Mar 2023
- Drugs of the Future
Bimiralisib. Phosphatidylinositol 3-kinase (PI3K)/mechanistic target of rapamycin (mTOR) inhibitor, Treatment of solid tumors, Treatment of lymphoma
- 1 Mar 2023
- Drugs of the Future
FAQs on Drugs of the Future
How long has Drugs of the Future been actively publishing? 
What is the publishing frequency of Drugs of the Future?
How many articles did Drugs of the Future publish last year?
What is the eISSN & pISSN for Drugs of the Future?
What is Citescore for Drugs of the Future?
What is SNIP score for Drugs of the Future?
What is the SJR for Drugs of the Future?
Who is the publisher of Drugs of the Future?
